KOSDAQBiotech & Pharma096530

Seegene

₩23,650▼ 1.25%2026-11-18 close
Market Cap
₩1.1T
Turnover
₩5.1B
Volume
220K
Shares out.
46.7M
PER
26.8×
PBR
1.3×
EPS
₩896
Dividend Yield
4.17%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩1,000 per share · Prices as of the 2026-11-18 close

01

Report overview

Seegene: Non-respiratory growth meets slowing quarterly profit

Seegene returned to annual operating profit in 2025 on growth in non-respiratory diagnostic reagents, but operating profit has declined for two consecutive quarters since the Q1 2026 peak, and Q3 2026 swung to a controlling-shareholder net loss.

  1. 1

    FY2025 revenue was KRW 474.2 billion, up 14.5% year on year, and operating profit of KRW 34.5 billion marked a return to profit.

  2. 2

    Non-respiratory product sales were KRW 62.4 billion in Q3 2026 preliminary results announced on November 6, 2026, up 12.3% year on year.

  3. 3

    The FY2024 operating loss of KRW 16.5 billion reflected large one-time COVID-19-related costs, and the company said operating profit excluding them would have been KRW 5.5 billion.

  4. 4

    Q3 2026 operating profit rose 21.2% year on year to KRW 11.6 billion, but a controlling-shareholder net loss of KRW 18.8 billion marked a swing to a loss, so operating and net results moved in opposite directions.

  5. 5

    Estimates from Korea IR Consortium (reported around August 2026) and Sangsangin Securities (reported October 2026) both put FY2026 operating profit at KRW 76.5 billion, but revenue estimates differ at KRW 524.4 billion and KRW 533.6 billion, leaving a wide full-year range.

02

Business structure

Seegene is a global molecular diagnostics total solution company that supplies infectious disease test reagents and instruments based on PCR (polymerase chain reaction) gene amplification technology.

In FY2025 consolidated sales, diagnostic reagents accounted for 78.9%, instruments 16.1%, and other businesses 5.0%, and within diagnostic reagents the gastrointestinal (GI) product line was the largest at 25.4%.

Non-respiratory products consist of GI, human papillomavirus (HPV), and sexually transmitted infection (STI) tests, and their FY2025 sales rose 21.3% to KRW 215.2 billion.

According to Sangsangin Securities' tally, non-respiratory diagnostic reagent sales in H1 2026 reached KRW 128.6 billion, up 27.3%, outpacing total sales growth. Respiratory product sales move with the seasons, and the non-respiratory syndromic product lines are offsetting that volatility.

By region, Europe was the largest at 59.1% in Q3 2026 preliminary results, followed by Asia at 15.8%, Latin America at 13.0%, Korea at 7.3%, and North America at 4.8%. Exports accounted for 92.8% of FY2025 sales, so the company is highly exposed to overseas demand and exchange rates.

The French subsidiary began direct sales in July 2026, shifting away from a distributor-centered model. Customers fall into private testing markets and public tender markets, and the company plans to expand into public tenders and the HPV testing market.

On competition, Seegene emphasizes its proprietary syndromic PCR technology that detects multiple pathogens at once. Unlike HLB or SK Bioscience, whose focus is on new drugs and vaccines, Seegene's core business is diagnostic reagents and instruments.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩113.5B₩9.6B8.5%
2025Q4₩130.6B₩6.9B5.3%
2026Q1₩129.1B₩23.6B18.2%
2026Q2₩136B₩21.6B15.9%
2026Q3₩123.1B₩11.6B9.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩853.6B₩196.5B₩182.1B23.0%15.9%20.9%
2023₩367.4B-₩30.1B₩700M−8.2%0.1%21.5%
2024₩414.3B-₩16.5B-₩20.3B−4.0%−2.1%22.8%
2025₩474.2B₩34.5B₩48.3B7.3%4.8%21.7%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

Annual results read as two overlapping trends: the post-COVID-19 reset and a recovery led by non-COVID products.

Revenue fell from KRW 853.6 billion in 2022 to KRW 367.4 billion in 2023, a 57.0% decline, then rose 12.8% to KRW 414.3 billion in 2024 and 14.5% to KRW 474.2 billion in 2025, which is two consecutive years of growth from 2024 through 2025. Among FY2022 to FY2025, 2022 was the largest year and 2023 the smallest.

Operating profit moved from KRW 196.5 billion in 2022 to an operating loss of KRW 30.1 billion in 2023, which turned the business into a loss, then to an operating loss of KRW 16.5 billion in 2024, where the loss narrowed from the prior year.

The 2024 loss reflected large one-time COVID-19-related costs, and in its preliminary FY2024 results announced in February 2025 the company said operating profit excluding them would have been KRW 5.5 billion. Operating profit returned to KRW 34.5 billion in 2025, a swing back to profit.

The operating margin went from 23.0% in 2022 to -8.2% in 2023 and -4.0% in 2024, before reaching 7.3% in 2025. According to press reports, the cost of sales ratio fell from 42.4% in 2024 to 35.9% in 2025.

Net income attributable to controlling shareholders was KRW 182.1 billion in 2022, KRW 669 million in 2023 (down 99.6%), a net loss of KRW 20.3 billion in 2024, and KRW 48.3 billion in 2025, while net income including non-controlling interests was a different figure in each year.

Quarterly operating profit was KRW 9.61 billion in Q3 2025 and KRW 6.95 billion in Q4 2025 (down 27.7% quarter on quarter), then peaked at KRW 23.6 billion in Q1 2026 (up 238.9%).

It then fell to KRW 21.6 billion in Q2 2026 (down 8.3%) and KRW 11.6 billion in Q3 2026 (down 46.1% quarter on quarter, up 21.2% year on year), a two-quarter decline in a row.

Controlling-shareholder net income went from KRW 34.7 billion in Q1 2026 to KRW 25.9 billion in Q2 2026, then swung to a controlling-shareholder net loss of KRW 18.8 billion in Q3 2026, so profit and net results moved in different directions.

Net income attributable to controlling shareholders for the last four quarters, from Q4 2025 to Q3 2026, totaled KRW 46.8 billion. Operating cash flow went from KRW 319 billion in 2022 to KRW 94.9 billion in 2023 and KRW 85.4 billion in 2024, then recovered to KRW 149.3 billion in 2025.

05

Industry analysis

The molecular diagnostics market grew rapidly on COVID-19 testing demand in 2020 and 2021 and is being reshaped around non-COVID products after the shift to endemic conditions. Seegene's sales reached KRW 1.37 trillion in 2021, reported as a record high, and adjustments continued from the second half of 2022.

The market's center of gravity is moving from respiratory testing toward non-respiratory tests such as HPV, STI, and GI. The testing method is also changing, and the company said demand for PCR-based tests for STI and GI products has increased.

In HPV, major tender wins and wider entry into screening markets are cited as drivers of sales. In cycle terms, revenue recovered from KRW 853.6 billion in 2022 through the 2023 trough to KRW 474.2 billion in 2025, but it remains below the 2022 level.

The competitive landscape splits between respiratory-focused tests and non-respiratory multiplex tests, and Seegene presents its syndromic PCR portfolio as a strength in the latter.

Because overseas sales make up most of revenue, tender and sales conditions in European markets and exchange rate moves directly affect results. In its Q3 2025 results, the company cited higher financial income from euro exchange rate movements as one factor in cost efficiency.

06

Outlook

The company's stated direction has three parts: expanding the market for existing products, upgrading next-generation diagnostic solutions, and strengthening its European sales network.

In the Q3 2026 results release, CFO Kim Jung-yong said non-respiratory product lines such as HPV, GI, and STI are growing evenly and diversifying the sales base, and the company stated its intent to strengthen medium- to long-term growth drivers.

In Europe, the company plans to develop the French subsidiary as a key hub for European operations alongside the Italian and German subsidiaries. It plans to keep its private market sales base while expanding into public tender markets and the HPV testing field.

The source material does not include a company revenue or operating profit guidance figure, so broker estimates serve as the reference for the full-year outlook.

Korea IR Consortium estimated FY2026 revenue at KRW 524.4 billion, operating profit at KRW 76.5 billion, and an operating margin of 14.6%, in a report from around August 2026, a forecast that assumes a return to a double-digit margin.

In an October 2026 report, Sangsangin Securities estimated non-respiratory diagnostic reagent sales at KRW 262.6 billion, up 22.0% year on year, total consolidated revenue at KRW 533.6 billion, and operating profit at KRW 76.5 billion.

Both estimates share the same operating profit level but differ on revenue, so whether full-year operating profit reaches that level will become clear with the Q4 2026 preliminary results and the 2026 annual report. How much the seasonal recovery in respiratory products feeds into Q4 results is another item to track.

07

Valuation

PER
26.8×
PBR
1.3×
ROE
4.7%
EPS
₩896
BPS
₩18,903
Dividend per share
₩1,000

The main variable in Seegene's valuation is that its earnings recovery is still at an early stage. Because the company only returned to profit in 2025, its earnings base is short, and earnings multiples are hard to interpret using a record that includes loss-making years.

Net income attributable to controlling shareholders over the last four quarters totals KRW 46.8 billion, so the durability of quarterly profit has not yet built up.

The price-to-book ratio sits in a range where the stock trades at a premium to book value, and because most of total equity belongs to controlling shareholders, equity-based comparisons are relatively straightforward. Dividends are a line item to review alongside earnings trends, given the volatility of profit.

The operating margin rose from -4.0% in 2024 to 7.3% in 2025, but operating profit fell in Q2 and Q3 2026, so the pace of margin recovery is mixed. Whether Q4 results mark a trend change or reflect seasonal effects will change how the same share price reads against earnings. Direct comparison with listed peers in the same sector is limited because their business structures differ.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Even growth in non-respiratory product lines

Non-respiratory product sales reached KRW 62.4 billion in Q3 2026 preliminary results announced on November 6, 2026, up 12.3% year on year. By line, HPV rose 19.7%, GI 12.6%, and STI 6.7%. According to Sangsangin Securities, non-respiratory diagnostic reagent sales rose 27.3% in H1 2026, faster than total sales.

A structure in which non-respiratory sales offset respiratory seasonality is cited as the main bullish argument.

Improving profit structure

The operating margin improved from -4.0% in 2024 to 7.3% in 2025, a return to profitability. Press reports said the cost of sales ratio fell from 42.4% in 2024 to 35.9% in 2025. Q1 2026 operating profit of KRW 23.6 billion was the peak of the quarterly run, and operating profit stayed positive in Q2 and Q3 2026. Cost and SG&A efficiency can be read as raising the floor for margins.

Shift to direct sales in Europe

Europe accounted for 59.1% of sales in Q3 2026 preliminary results, the largest share. The French subsidiary began direct sales in July 2026, shifting from a distributor-centered model to a subsidiary-led one. The company aims to keep its private market base while expanding into public tenders and HPV testing. Whether direct control of sales lifts margins is an open question to track.

09

Bear factors

Quarterly profit slowdown and swing to loss

Operating profit fell from KRW 23.6 billion in Q1 2026 to KRW 21.6 billion in Q2 and KRW 11.6 billion in Q3, a two-quarter decline in a row. Controlling-shareholder net income swung to a net loss of KRW 18.8 billion in Q3 2026, from KRW 14.6 billion of profit a year earlier.

Because quarterly results swing with respiratory demand, the durability of quarterly profit has not yet been confirmed over several quarters. The reason operating and net results diverged needs to be checked in the annual report.

Incomplete recovery in revenue base

FY2025 revenue of KRW 474.2 billion is slightly more than half of the KRW 853.6 billion recorded in 2022. Revenue fell to KRW 367.4 billion in 2023, showing high volatility after COVID-19. FY2025 operating profit of KRW 34.5 billion is small compared with the boom years. Whether the shift to non-COVID markets is complete needs more confirmation from full-year results.

Overseas dependence and currency exposure

Exports accounted for 92.8% of FY2025 sales, so overseas demand and exchange rate moves have a direct effect. Europe's 59.1% share of Q3 2026 preliminary sales shows high concentration in one region.

The French direct-sales operation began in July 2026, but its early results are not yet fully visible in quarterly figures.

10

Risk factors

Public tender outcomes

Because major tender wins are cited as a driver of HPV sales growth, revenue could shift with tender outcomes. Expanding into public tenders is a company plan, but pricing and award results depend on external conditions. Tender results are likely to be a source of quarter-to-quarter volatility.

Exchange rates and financial income

In its Q3 2025 results, the company cited higher financial income from euro exchange movements as a factor in cost efficiency. With 92.8% of sales from exports, a change in exchange rate direction would affect financial and non-operating results.

Whether the Q3 2026 swing to a controlling-shareholder net loss was linked to financial income changes needs to be checked in the annual report notes.

Seasonality and estimate gaps

Respiratory product sales vary by quarter with the seasons, and Q3 2026 revenue fell 9.4% from the prior quarter. Estimates from brokers also differ on FY2026 revenue at KRW 524.4 billion and KRW 533.6 billion, widening the full-year range. If actual results diverge from these estimates, the reading of quarterly results could shift.

11

What to watch next

  1. Around February 2027

    Preliminary Q4 and full-year 2026 results. Last year's preliminary FY2024 results came out on February 26, 2025, so a similar timing is possible. Whether FY2026 operating profit reaches the broker estimate level of KRW 76.5 billion, and how much the respiratory recovery lifts Q4, are the key checks.

  2. Late March 2027

    Filing of the 2026 annual report, the next periodic report. It will add full-year operating margin, debt ratio, and cash flow to the disclosed record. The notes should show whether the cause of the Q3 2026 swing to a controlling-shareholder net loss is explained.

  3. December 2026 to H1 2027

    Track early results from direct sales by the French subsidiary and public tender outcomes. Whether Europe's share stays near 59.1% and whether the direct model lifts non-respiratory sales such as HPV are the key checks.

  4. At the Q1 2027 results release

    Check whether operating profit holds after the Q1 2026 peak. Whether the higher non-respiratory share has reduced seasonal swings is the key data point.

12

Overall view

Seegene's sales shrank after the COVID-19 boom, then turned to recovery in 2024 and 2025, and operating profit swung back to profit in 2025. Non-respiratory product lines such as HPV, GI, and STI are driving growth, and their H1 2026 diagnostic reagent sales growth outpaced the total.

On profitability, a lower cost of sales ratio and cost efficiency lifted the operating margin to 7.3%. However, operating profit declined for two consecutive quarters in Q2 and Q3 2026, and Q3 swung to a controlling-shareholder net loss of KRW 18.8 billion.

Europe's 59.1% share and exports at 92.8% of sales show a structure highly exposed to overseas demand and exchange rates. Broker estimates agree on FY2026 operating profit of KRW 76.5 billion but differ on revenue, so the gap will narrow only when full-year figures are reported.

The next checkpoints are the Q4 2026 preliminary results and the 2026 annual report, including its operating margin and the causes of the net loss.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. vegannews.co.kr
  2. getnews.co.kr
  3. rapportian.com
  4. monews.co.kr
  5. greened.kr
  6. srtimes.kr
  7. view.asiae.co.kr
  8. specialtimes.co.kr
  9. medipana.com
  10. medigatenews.com
  11. newsway.co.kr
  12. sedaily.com
  13. thebionews.net
  14. yakpum.co.kr
  15. goodkyung.com
  16. news.nate.com
  17. straightnews.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis